Brought to you by 
Epizyme closes $130mm public offering
13 Jan 2016
Executive Summary
Epizyme Inc. (epigenetic cancer therapies) netted $130mm through the public sale of 15.3mm shares (including the overallotment) at $9. Proceeds will fund ongoing development of lead project tazemetostat outside of Japan (including Phase II trials for non-Hodgkin lymphoma, INI1-negative tumors, and synovial sarcoma, and planned studies for diffuse large B-cell lymphoma, B-cell non-Hodgkin lymphoma, and mesothelioma) and the initiation of activities supporting the eventual market launch of the compound.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Epizyme closes $130mm public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice